Revance Therapeutics, Inc. (RVNC)

NASDAQ: RVNC · IEX Real-Time Price · USD
31.70
+0.25 (0.79%)
At close: Mar 24, 2023, 4:00 PM
32.44
+0.74 (2.33%)
After-hours: Mar 24, 2023, 7:02 PM EDT
0.79%
Market Cap 2.62B
Revenue (ttm) 132.57M
Net Income (ttm) -356.42M
Shares Out 82.80M
EPS (ttm) -4.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 972,415
Open 31.24
Previous Close 31.45
Day's Range 30.20 - 32.09
52-Week Range 11.27 - 36.61
Beta 0.86
Analysts Buy
Price Target 37.06 (+16.91%)
Earnings Date May 9, 2023

About RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral can... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 6, 2014
Employees 495
Stock Exchange NASDAQ
Ticker Symbol RVNC
Full Company Profile

Financial Performance

In 2022, RVNC's revenue was $132.57 million, an increase of 70.40% compared to the previous year's $77.80 million. Losses were -$356.42 million, 26.7% more than in 2021.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for RVNC stock is "Buy." The 12-month stock price forecast is $37.06, which is an increase of 16.91% from the latest price.

Price Target
$37.06
(16.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor

Investors in Revance Therapeutics Inc. (NASDAQ: RVNC) shouldn't have much to frown about after the stock gapped up 54.34% on January 9, and built upon those gains in February.

3 weeks ago - MarketBeat

Revance Therapeutics, Inc. (RVNC) Reports Q4 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -75% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st...

3 weeks ago - Zacks Investment Research

Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update

Q4 and full year 2022 total revenue of $49.9 million and $132.6 million, a YoY increase of 92% and 70%, respectively.

3 weeks ago - Business Wire

Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, a...

1 month ago - Business Wire

Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q4 Earnings Expected to Decline

Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

What Makes Revance Therapeutics, Inc. (RVNC) a Strong Momentum Stock: Buy Now?

Does Revance Therapeutics, Inc. (RVNC) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago - Zacks Investment Research

3 Pharma Stocks That Will Mint Millionaires

In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB) climbed 6% so far this year.

Other symbols: IMCRSWAV
1 month ago - InvestorPlace

Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the...

2 months ago - Zacks Investment Research

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year ...

2 months ago - Business Wire

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License...

2 months ago - Business Wire

Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will...

4 months ago - Business Wire

Revance to Participate in the Stifel 2022 Healthcare Conference

NASHVILLE, Tenn.

4 months ago - Business Wire

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

4 months ago - Zacks Investment Research

Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update

Received FDA approval for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines

4 months ago - Business Wire

Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Should You Buy?

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Revance Appoints David A. Hollander, M.D.

NASHVILLE, Tenn.

5 months ago - Business Wire

Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ for Injection at the 2022 ASDS Annual Meeting

5 months ago - Business Wire

Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

6 months ago - Business Wire

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ For Injection in the Aesthetic Surgery Journal

6 months ago - Business Wire

Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ Injection for the Treatment of Upper Limb Spasticity at MDS

6 months ago - Business Wire

Revance Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

6 months ago - Business Wire

Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

6 months ago - Business Wire